A pioneering advancement in the field of single-cell analysis has emerged with Sphere Bio's introduction of the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit. Compatible with their latest Cyto-Mine® Chroma platform, this multiplexed assay kit allows researchers to simultaneously evaluate cell productivity and viability, streamlining workflows while enhancing the quality of selected cells. The innovation reduces development timelines from months to hours and offers a more cost-effective solution compared to traditional methods.
The new assay kit provides advanced multiplexing capabilities that ensure optimal selection outcomes by detecting secreted antibodies and assessing cell surface viability stains. This integrated approach significantly lowers the risk of false positives and ensures only the most productive clones are chosen for further analysis or development. Additionally, on-board monoclonality assurance adds another layer of reliability to the process, marking a significant milestone in Sphere Bio’s mission to set new industry standards for efficiency and reliability.
Pioneering Technology for Streamlined Workflows
Sphere Bio's Cyto-Cellect Human IgG Kappa and Viability Assay Kit represents a breakthrough in single-cell analysis technology. By enabling simultaneous detection of secreted antibodies and cell viability assessment, it optimizes the selection process of high-producing clones. This capability not only accelerates research timelines but also enhances the overall efficiency of cell line development projects.
This novel assay kit operates in conjunction with the Cyto-Mine Chroma platform, utilizing fluorescence-based assays within picodroplets. This system evaluates cells based on secreted, surface, and intracellular markers, ensuring precise and reliable results. The integration of multiplexing features facilitates streamlined workflows, reducing the time required for cell line development from months to mere hours. Moreover, the cost-effectiveness of this method positions it as a superior alternative to conventional techniques. Researchers can now focus on selecting the healthiest, most productive cells without compromising on speed or accuracy. Preliminary findings indicate that approximately five percent of selected high-producing clones exhibit apoptotic characteristics, highlighting the importance of early-stage screening to eliminate these false positives.
Unprecedented Precision and Industry Leadership
Through its commitment to advancing scientific discovery, Sphere Bio continues to redefine industry benchmarks with transformative solutions. The Cyto-Cellect Human IgG Kappa and Viability Assay Kit exemplifies this dedication by offering unparalleled precision in single-cell analysis. The integration of viability assessment alongside antibody detection ensures only the most robust cells are selected, significantly improving research efficiency and outcomes.
The launch of this innovative assay kit marks a crucial step forward in Sphere Bio's product portfolio expansion. It underscores the company's mission to deliver cutting-edge tools that enhance the reliability and efficiency of cell line development processes. Dr. Xin Liu, Senior Product Manager for Assays and Applications at Sphere Bio, emphasizes the game-changing nature of this new assay kit. By combining viability evaluation with antibody detection, researchers can achieve enhanced precision and reliability in their work. Furthermore, Dr. Maryam Ahmadi, Director of Science at Sphere Bio, highlights the significance of this development within the broader context of the company's roadmap for multiplex assays compatible with the Chroma platform. This ongoing commitment to expanding their portfolio of advanced tools promises to accelerate scientific progress across various fields of study.